GSK (GSK) Touches All-Time High on Potential Exemption From Trump Tariff

We recently published 11 Stocks Crushing Wall Street With Whopping Gains. GSK plc (NYSE:GSK) is one of the top performers on Tuesday.

Shares of GSK rallied for a third straight day on Tuesday to hit a new all-time high, as investors gobbled up shares in US-based pharmaceutical companies a day ahead of the official imposition of a hefty tariff on imported drugs.

During the session, GSK plc (NYSE:GSK) jumped to a new all-time high of $43.32 before giving up marginal gains to finish the day just up by 5.05 percent at $43.17 apiece.

While a London-based company, investors posted confidence on GSK plc (NYSE:GSK) following announcements that it would invest $30 billion in the US over the next five years.

Under President Donald Trump’s new tariff rules, imported drug products will be slapped as much as 100 percent levy, but those that will invest in manufacturing in the US could be exempted. The announcement sparked investor optimism that GSK plc (NYSE:GSK) will be spared from tariffs.

In other news, the company announced changes in its leadership following the resignation of Emma Walmsley as its chief executive officer. She will be replaced by incumbent chief commercial officer, Luke Miels, effective January 1, 2026.

“2026 is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership,” Walmsley was quoted as saying in the company’s statement.

“Today, GSK is a biopharma innovator, with far stronger momentum and prospects than nine years ago,” she noted.

While we acknowledge the potential of GSK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.